Gyre Therapeutics will present positive Phase 3 results for Hydronidone in liver fibrosis at The Liver Meeting 2025.
Quiver AI Summary
Gyre Therapeutics has announced that it will present positive results from a Phase 3 clinical trial of Hydronidone, an innovative anti-fibrotic therapy aimed at treating liver fibrosis in patients with chronic hepatitis B, at The Liver Meeting® 2025. The meeting, organized by the American Association for the Study of Liver Diseases, will take place from November 7-10 in Washington D.C. The trial's results will be shared by Prof. Lungen Lu, M.D. from Shanghai General Hospital, and the presentation has been designated as a Poster of Distinction. Gyre Therapeutics, based in San Diego, focuses on developing and commercializing Hydronidone while also pursuing a broad pipeline in China through its subsidiary, Gyre Pharmaceuticals.
Potential Positives
- Gyre Therapeutics announced positive results from a Phase 3 clinical trial for Hydronidone, a promising anti-fibrotic agent targeted at liver fibrosis in chronic hepatitis B.
- The presentation of the trial results at The Liver Meeting® 2025, a prestigious annual gathering for liver disease research, enhances the company's visibility and credibility in the medical community.
- The abstract's selection as a Poster of Distinction highlights the significance of the research and the potential impact of Hydronidone in treating liver fibrosis.
- Gyre Therapeutics' strategy encompasses both U.S. and Chinese markets, indicating a robust pipeline and potential for international growth in various therapeutic areas.
Potential Negatives
- Although the Phase 3 trial results were described as positive, the release does not provide specific data or statistics to support this claim, which may lead to skepticism among investors and stakeholders.
- The press release primarily highlights the upcoming presentation at an industry meeting without addressing potential challenges or competition faced by Hydronidone in the market.
- The focus on a single drug, Hydronidone, could raise concerns about the company's reliance on a one-product strategy, potentially exposing it to risks related to market acceptance and regulatory approval.
FAQ
What is Gyre Therapeutics focused on?
Gyre Therapeutics is dedicated to advancing fibrosis-first therapies for organ systems affected by chronic diseases.
What is Hydronidone and its purpose?
Hydronidone is a novel anti-fibrotic agent used for treating liver fibrosis in chronic hepatitis B.
When and where will the Phase 3 trial results be presented?
The results will be presented on November 7, 2025, at The Liver Meeting® in Washington D.C.
Who is the presenting author for the Phase 3 trial results?
Prof. Lungen Lu, M.D., from Shanghai General Hospital will present the trial results.
What is Gyre's strategy in liver fibrosis treatment?
Gyre's strategy involves mechanistic studies and clinical trials focused on liver fibrosis caused by chronic hepatitis B.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GYRE Insider Trading Activity
$GYRE insiders have traded $GYRE stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $GYRE stock by insiders over the last 6 months:
- SONGJIANG MA (President) has made 0 purchases and 8 sales selling 12,740 shares for an estimated $138,682.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GYRE Hedge Fund Activity
We have seen 33 institutional investors add shares of $GYRE stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 295,399 shares (+54.0%) to their portfolio in Q2 2025, for an estimated $2,171,182
- SBI SECURITIES CO., LTD. added 108,670 shares (+87.9%) to their portfolio in Q2 2025, for an estimated $798,724
- GEODE CAPITAL MANAGEMENT, LLC added 89,390 shares (+28.6%) to their portfolio in Q2 2025, for an estimated $657,016
- VANGUARD GROUP INC added 53,221 shares (+4.9%) to their portfolio in Q2 2025, for an estimated $391,174
- STATE STREET CORP added 48,995 shares (+38.0%) to their portfolio in Q2 2025, for an estimated $360,113
- STATE OF WISCONSIN INVESTMENT BOARD added 37,670 shares (+inf%) to their portfolio in Q2 2025, for an estimated $276,874
- NORTHERN TRUST CORP added 35,319 shares (+32.7%) to their portfolio in Q2 2025, for an estimated $259,594
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GYRE Analyst Ratings
Wall Street analysts have issued reports on $GYRE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 10/10/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/26/2025
To track analyst ratings and price targets for $GYRE, check out Quiver Quantitative's $GYRE forecast page.
$GYRE Price Targets
Multiple analysts have issued price targets for $GYRE recently. We have seen 2 analysts offer price targets for $GYRE in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Roger Song from Jefferies set a target price of $16.0 on 10/10/2025
- Matthew Keller from HC Wainwright & Co. set a target price of $18.0 on 08/26/2025
Full Release
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it will be presenting results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent that inhibits hepatic stellate cell (HSC) activation and promotes HSC apoptosis, for the treatment of liver fibrosis in chronic hepatitis B, at The Liver Meeting® 2025, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting® 2025 is being held November 7-10, 2025, in Washington D.C.
This abstract has been selected as a Poster of Distinction , and the details are below:
Title: Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B
Presenting Author: Prof. Lungen Lu, M.D., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Session: Hepatitis B (“1187-1367”)
Date/Time: Friday, November 7, 2025, 8:00 a.m. – 5:00 p.m. Eastern Time
Publication Number: 1121
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY
®
, and development programs for F573, F528, and F230.
For Investors:
David Zhang
Gyre Therapeutics
[email protected]
